MSB 7.69% $1.19 mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-85

  1. 604 Posts.
    lightbulb Created with Sketch. 53
    But they still seem confident.
    It is going to take a lot longer than expected.
    we can wait but the only thing that is concerning is the cash burn rate for the company to conduct additional trials. They should have those from ADRS anyway.
    What a day!
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.